These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 17448130)

  • 1. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes.
    ; Zeitler P; Epstein L; Grey M; Hirst K; Kaufman F; Tamborlane W; Wilfley D
    Pediatr Diabetes; 2007 Apr; 8(2):74-87. PubMed ID: 17448130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical trial to maintain glycemic control in youth with type 2 diabetes.
    ; Zeitler P; Hirst K; Pyle L; Linder B; Copeland K; Arslanian S; Cuttler L; Nathan DM; Tollefsen S; Wilfley D; Kaufman F
    N Engl J Med; 2012 Jun; 366(24):2247-56. PubMed ID: 22540912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study.
    Narasimhan S; Weinstock RS
    Mayo Clin Proc; 2014 Jun; 89(6):806-16. PubMed ID: 24702733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY.
    TODAY Study Group
    Diabetes Care; 2013 Jun; 36(6):1749-57. PubMed ID: 23704674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience.
    Marcus MD; Wilfley DE; El Ghormli L; Zeitler P; Linder B; Hirst K; Ievers-Landis CE; van Buren DJ; Walders-Abramson N;
    Pediatr Obes; 2017 Aug; 12(4):337-345. PubMed ID: 27161901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
    Derosa G; Gaddi AV; Piccinni MN; Ciccarelli L; Salvadeo S; Peros E; Ghelfi M; Ferrari I; Cicero AF
    Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
    Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
    Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
    Viberti G; Kahn SE; Greene DA; Herman WH; Zinman B; Holman RR; Haffner SM; Levy D; Lachin JM; Berry RA; Heise MA; Jones NP; Freed MI
    Diabetes Care; 2002 Oct; 25(10):1737-43. PubMed ID: 12351470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study.
    TODAY Study Group
    Int J Obes (Lond); 2010 Feb; 34(2):217-26. PubMed ID: 19823189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
    Beale S; Bagust A; Shearer AT; Martin A; Hulme L
    Pharmacoeconomics; 2006; 24 Suppl 1():21-34. PubMed ID: 16800160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postintervention Effects of Varying Treatment Arms on Glycemic Failure and β-Cell Function in the TODAY Trial.
    TODAY Study Group
    Diabetes Care; 2021 Jan; 44(1):75-80. PubMed ID: 33290248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
    Huang Z; Wan X; Liu J; Deng W; Chen A; Liu L; Liu J; Wei G; Li H; Fang D; Li Y
    Diabetes Technol Ther; 2013 Oct; 15(10):859-69. PubMed ID: 23991629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
    Shearer AT; Bagust A; Ampudia-Blasco FJ; Martínez-Lage Alvarez B; Pérez Escolano I; París G
    Pharmacoeconomics; 2006; 24 Suppl 1():49-59. PubMed ID: 16800162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
    Bailey CJ; Bagdonas A; Rubes J; McMorn SO; Donaldson J; Biswas N; Stewart MW
    Clin Ther; 2005 Oct; 27(10):1548-61. PubMed ID: 16330291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Surgical and Medical Therapy for Type 2 Diabetes in Severely Obese Adolescents.
    Inge TH; Laffel LM; Jenkins TM; Marcus MD; Leibel NI; Brandt ML; Haymond M; Urbina EM; Dolan LM; Zeitler PS;
    JAMA Pediatr; 2018 May; 172(5):452-460. PubMed ID: 29532078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Jonas DE; Vander Schaaf EB; Riley S; Allison BA; Middleton JC; Baker C; Ali R; Voisin CE; LeBlanc ES
    JAMA; 2022 Sep; 328(10):968-979. PubMed ID: 36098720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.